Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Summary Background Initial treatment of acute promyelocytic leukaemia traditionally involves tretinoin (all-trans retinoic acid) combined with anthracycline-based risk-adapted chemotherapy, with arsenic trioxide being the treatment of choice at relapse. To try to reduce the relapse rate, we combined...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet. Haematology 2015-09, Vol.2 (9), p.e357-e366
Hauptverfasser:	Iland, Harry J, Prof, Collins, Marnie, BSc, Bradstock, Ken, Prof, Supple, Shane G, PhD, Catalano, Alberto, PhD, Hertzberg, Mark, Prof, Browett, Peter, Prof, Grigg, Andrew, Prof, Firkin, Frank, PhD, Campbell, Lynda J, FRCPA, Hugman, Amanda, FRACP, Reynolds, John, PhD, Di Iulio, Juliana, PhD, Tiley, Campbell, FRACP, Taylor, Kerry, FRACP, Filshie, Robin, FRACP, Seldon, Michael, FRACP, Taper, John, FRACP, Szer, Jeff, Prof, Moore, John, FRACP, Bashford, John, FRACP, Seymour, John F, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols Arsenicals - therapeutic use Australia Consolidation Chemotherapy Female Hematology, Oncology and Palliative Medicine Humans Leukemia, Promyelocytic, Acute - drug therapy Lymphoma - drug therapy Male Middle Aged Neoplasm Recurrence, Local - drug therapy Oxides - therapeutic use Remission Induction Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!